Dayer J M, Feige U, Edwards C K, Burger D
Division of Immunology and Allergy, University Hospital, Geneva, Switzerland.
Curr Opin Rheumatol. 2001 May;13(3):170-6. doi: 10.1097/00002281-200105000-00004.
Recent research has shown that in the processes of rheumatoid arthritis (RA), interleukin (IL)-1 is one of the pivotal cytokines in initiating disease, and the body's natural response, IL-1 receptor antagonist (IL-1Ra), has been shown conclusively to block its effects. In laboratory and animal studies inhibition of IL-1 by either antibodies to IL-1 or IL-1Ra proved beneficial to the outcome. To date, two large well-controlled studies in patients with RA led to the conclusion that IL-1Ra is clinically effective and that it slows progression of bone damage as measured radiographically. Being a specific, selective inhibitor of the IL-1 pathway, IL-1Ra could constitute an important new approach to treating patients with RA that significantly reduces the signs and symptoms of the disease, reduces joint destruction and up to now has proved safe and well tolerated.
近期研究表明，在类风湿关节炎（RA）的发病过程中，白细胞介素（IL）-1是引发疾病的关键细胞因子之一，而人体的天然反应——IL-1受体拮抗剂（IL-1Ra）已被确凿证明可阻断其作用。在实验室和动物研究中，通过抗IL-1抗体或IL-1Ra抑制IL-1被证明对病情转归有益。迄今为止，两项针对RA患者的大型严格对照研究得出结论，IL-1Ra在临床上是有效的，并且通过影像学测量发现它可减缓骨损伤的进展。作为IL-1通路的特异性、选择性抑制剂，IL-1Ra可能成为治疗RA患者的一种重要新方法，该方法可显著减轻疾病的体征和症状，减少关节破坏，并且迄今为止已证明其安全性良好且耐受性佳。
